Medication info

Aminomixpery Injection

Prescription medicationSolutionIntravenous injection
Ingredient · strength
L-Alanine›0.49g / 100mLL-Arginine›0.42g / 100mLGlycine›0.385g / 100mLL-Histidine›0.105g / 100mLL-Isoleucine›0.175g / 100mLL-Leucine›0.259g / 100mLL-Lysine Acetate›0.326g / 100mLL-Methionine›0.151g / 100mLL-Phenylalanine›0.179g / 100mLL-Proline›0.392g / 100mLL-Serine›0.228g / 100mLTaurine›0.035g / 100mLL-Threonine›0.154g / 100mLL-Tryptophan›0.07g / 100mLL-Tyrosine›0.014g / 100mLL-Valine›0.217g / 100mLCalcium Chloride Hydrate›0.024g / 100mLSodium Glycerophosphate›0.178g / 100mLMagnesium Sulfate Heptahydrate›0.078g / 100mLPotassium Chloride›0.141g / 100mLSodium Acetate Hydrate›0.116g / 100mLGlucose Monohydrate›6.93g / 100mL
Manufacturer / importer
Fresenius Kabi Korea Ltd.
Appearance
This medication is a clear, colorless to pale yellow solution without any particulates, contained in a bag divided into two compartments.
Packaging
1000 mL/bag [x 1 (Component A: 500 mL, Component B: 500 mL)], 1000 mL/bag [x 6 (Component A: 500 mL, Component B: 500 mL)], 1500 mL/bag [x 1 (Component A: 750 mL, Component B: 750 mL)], 1500 mL/bag [x 4 (Component A: 750 mL, Component B: 750 mL)], 2000 mL/bag [x 1 (Component A: 1000 mL, Component B: 1000 mL)], 200
Approval status
Active

MFDS item code 202301794 · Approved 2023.06.09 · Insurance code 650902171

Summary

Main use
Improvement of nutritional status in adults through intravenous nutritional supplementation (e.g., amino acids and electrolytes)
Who receives it
Adults
Adult administration
Adults: The dose should be adjusted according to the requirements for amino acids, glucose, electrolytes, and fluids, as well as the patient's clinical condition and nutritional status. For parenteral nutrition, fluid replacement guidelines should also be considered in addition to the general principles and recommendations for the administration and dosing of amino acids, glucose, and electrolytes. If additional caloric requirements exist, these should be met by administering an adequate amount of lipid emulsions intravenously. Maximum daily dose: 40 ml/kg/day (equivalent to amino acids 1.4 g/kg/day and glucose 2.5 g/kg/day). Duration of treatment: The duration of intravenous administration depends on the patient's condition and nutritional requirements. Depending on the patient's clinical condition, consider intravenous infusion of lipids, vitamins, additional electrolytes, and trace elements. Administer intravenously via a peripheral or central vein. Maximum infusion rate: 2.9 ml/kg/hour (equivalent to amino acids 0.10 g/kg/hour and glucose 0.18 g/kg/hour). The recommended maximum infusion time is 24 hours.

Ingredients

Importer
Fresenius Kabi Korea Ltd.

Efficacy & effects

Improvement of nutritional status in adults through intravenous nutritional supplementation (e.g., amino acids and electrolytes)

View approved original text

This medication provides amino acids, electrolytes, and glucose intravenously to adult patients who cannot receive nutrition orally or via the gastrointestinal tract, thereby supplementing essential nutrients. This helps improve the nutritional status of the patient and supports overall health maintenance. Additionally, it effectively delivers essential nutrients when the gastrointestinal tract is unavailable, aiding the patient's recovery. This nutritional supply contributes to the physiological balance of the patient and normalizes body functions. Consequently, this medication is used safely and effectively in patients requiring non-oral nutritional support.

How it is given

Adult administration

Adults: The dose should be adjusted according to the requirements for amino acids, glucose, electrolytes, and fluids, as well as the patient's clinical condition and nutritional status. For parenteral nutrition, fluid replacement guidelines should also be considered in addition to the general principles and recommendations for the administration and dosing of amino acids, glucose, and electrolytes. If additional caloric requirements exist, these should be met by administering an adequate amount of lipid emulsions intravenously. Maximum daily dose: 40 ml/kg/day (equivalent to amino acids 1.4 g/kg/day and glucose 2.5 g/kg/day). Duration of treatment: The duration of intravenous administration depends on the patient's condition and nutritional requirements. Depending on the patient's clinical condition, consider intravenous infusion of lipids, vitamins, additional electrolytes, and trace elements. Administer intravenously via a peripheral or central vein. Maximum infusion rate: 2.9 ml/kg/hour (equivalent to amino acids 0.10 g/kg/hour and glucose 0.18 g/kg/hour). The recommended maximum infusion time is 24 hours.

Precautions

This medication must be used strictly according to the physician's instructions, and if any signs of anaphylaxis, such as fever, chills, rash, or difficulty breathing occur during use, administration should be immediately discontinued. When used in conjunction with intravenous calcium-containing preparations, precipitation may occur if mixed with ceftriaxone, and the same infusion device should not be used; if it is necessary to use the same infusion line, it should be thoroughly rinsed before and after administration. This medication should not be administered to certain patients, such as those with hypersensitivity to the components or congenital amino acid metabolism disorders, patients where the risk of fluid overload is contraindicated (e.g., with heart failure or pulmonary edema), those with severe liver or kidney dysfunction, patients with a history of myocardial infarction, and children under 2 years of age. Special precautions are required for patients with liver, kidney, heart diseases, diabetes, or electrolyte imbalances; regular monitoring and management of blood glucose, urea, ammonia, and electrolyte levels are necessary. This medication may cause injection site irritation, thrombophlebitis, allergic reactions, etc., so the injection site should be checked frequently, and any unusual symptoms should be addressed immediately. When starting treatment in patients with malnutrition, there is a risk of refeeding syndrome, and the infusion rate should be adjusted slowly with monitoring. During catheter insertion, strict aseptic procedures must be followed to reduce infection risk, and care must be taken not to exceed the recommended infusion rate. This medication contains glucose, potassium, and sodium, so care should be taken considering the component levels when administering it to patients with diabetes or impaired renal function. Safety has not been established for pregnant or nursing women, and it should only be administered when the therapeutic benefits outweigh the risks. Do not use if the packaging is damaged or if the contents are cloudy or contain particulates, and use mixed solutions immediately, discarding any remaining solution. Storage should be in a sealed container to avoid contact with air and kept at room temperature between 1 and 30 degrees Celsius. This storage method will maintain the medication’s effectiveness and prevent deterioration.

Side effects

Signs or symptoms of anaphylactic reaction (fever, chills, rash, difficulty breathing), allergic reactions, site of injection irritation, thrombophlebitis, nausea, vomiting, tremors, sweating, increase in body temperature

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to avoid contact with air and should ideally be kept at room temperature between 1 and 30 degrees Celsius. This storage method preserves the medication's efficacy and prevents degradation.

Appearance and packaging

Appearance

This medication is a clear, colorless to pale yellow solution without any particulates, contained in a bag divided into two compartments.

Package unit

1000 mL/bag [x 1 (Component A: 500 mL, Component B: 500 mL)], 1000 mL/bag [x 6 (Component A: 500 mL, Component B: 500 mL)], 1500 mL/bag [x 1 (Component A: 750 mL, Component B: 750 mL)], 1500 mL/bag [x 4 (Component A: 750 mL, Component B: 750 mL)], 2000 mL/bag [x 1 (Component A: 1000 mL, Component B: 1000 mL)], 200

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.